Investigational drug · Phase 3
TAK-771
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Primary Immunodeficiency Diseases (PID).
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "TAK-771"
First trial start
2022
Jan 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAK-771", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Multifocal Motor Neuropathy (MMN)
- Primary Immunodeficiency Diseases (PID)
Approved drugs for the same conditions: Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "TAK-771" as an intervention, largest first.
- A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05084053 · 26 participants · Start Jan 19, 2022 · Primary completion Oct 28, 2025
Drug: TAK-771 · For: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP); Multifocal Motor Neuropathy (MMN)
Sites: Nagakute, Japan; Nagoya, Japan; Toyoake, Japan · 23 sites in all
- A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05150340 · 16 participants · Start Jan 24, 2022 · Primary completion Aug 28, 2023
Drug: TAK-771 · For: Primary Immunodeficiency Diseases (PID)
Sites: Nagoya, Japan; Kitakyushu, Japan; Kurume, Japan · 12 sites in all
- A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) ParticipantsPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05513586 · 15 participants · Start Sep 13, 2022 · Primary completion Oct 30, 2025
Drug: TAK-771 · For: Primary Immunodeficiency Diseases (PID)
Sites: Nagoya, Japan; Kitakyushu, Japan; Yokohama, Japan · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.